FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Pierre Geborek

Research Profile

Chemicals & Drugs

Disorders

Geographic Areas

Sweden

Concepts & Ideas

Procedures

Co-author Network

Publications

TOP 3
Hamed Rezaei; Saedis Saevarsdottir; Ronald F van Vollenhoven; Pierre Geborek; Ingemar F Petersson; Kristina Forslind
Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial.
Pia Malcus Johnsson; Gunnel Sandqvist; Anna-Lena Sturesson; Magnus Tägil; Anders Gulfe; philippe kopylov; Pierre Geborek
Individualized outcome measures of daily activities are sensitive tools for evaluating hand surgery in rheumatic diseases.
Ronald F van Vollenhoven; Kristina Albertsson; Johan Bratt; Katerina Chatzidionysiou; Sofia Ernestam; Kristina Forslind; Pierre Geborek; Ingemar F Petersson
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Pierre Geborek (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Hamed Rezaei; Saedis Saevarsdottir; Ronald F van Vollenhoven; Pierre Geborek; Ingemar F Petersson; Kristina Forslind
Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial.
BMC musculoskeletal disorders 2013;14():79.
2012: Pia Malcus Johnsson; Gunnel Sandqvist; Anna-Lena Sturesson; Magnus Tägil; Anders Gulfe; philippe kopylov; Pierre Geborek
Individualized outcome measures of daily activities are sensitive tools for evaluating hand surgery in rheumatic diseases.
Rheumatology (Oxford, England) 2012;51(12):2246-51.
2012: Ronald F van Vollenhoven; Kristina Albertsson; Johan Bratt; Katerina Chatzidionysiou; Sofia Ernestam; Kristina Forslind; Pierre Geborek; Ingemar F Petersson
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.
Lancet 2012;379(9827):1712-20.
2012: Lars E Kristensen; Ingemar F Petersson; Tore Saxne; Pierre Geborek; L T H Jacobsson; Anna Jöud; Martin Englund
Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study.
Rheumatology (Oxford, England) 2012;51(2):243-9.
2012: Mohamed Abdgawad; Anders A Bengtsson; Pierre Geborek; Lena Gunnarsson; Lars Nilsson; Mårten Segelmark; Åsa Pettersson; Thomas Hellmark
Decreased neutrophil apoptosis in quiescent ANCA-associated systemic vasculitis.
PloS one 2012;7(3):e32439.
2012: Kaisa E Happonen; Dick Heinegård; R Hesselstrand; Tore Saxne; Maria Andersson; Anders A Bengtsson; Pierre Geborek; Anna M Blom
Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-α treatment.
Arthritis research & therapy 2012;14(1):R15.
2011: Johan A Karlsson; Lars Erik Kristensen; Martin Neovius; Jan-Åke Nilsson; Tore Saxne; Anders Gülfe; Pierre Geborek
National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients.
Annals of the rheumatic diseases 2011;70(12):2163-6.
2011: Meliha C Kapetanovic; Carmen Roseman; Tore Saxne; Lennart Truedsson; Göran Jönsson; Pierre Geborek
Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.
Arthritis and rheumatism 2011;63(12):3723-32.
2011: Saedis Saevarsdottir; Helena Wallin; Maria Seddighzadeh; Sofia Ernestam; Pierre Geborek; Ingemar F Petersson; Johan Bratt; Ronald van Vollenhoven
Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial.
Annals of the rheumatic diseases 2011;70(3):469-75.
2011: M Neovius; Jf Simard; Annika Sundström; L Jacobsson; Pierre Geborek; T Saxne; Nils Feltelius; Lars Klareskog; Johan Askling
Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register.
Annals of the rheumatic diseases 2011;70(3):516-9.
2011: Meliha C Kapetanovic; Elisabet Lindqvist; Tore Saxne; Jakob Algulin; Kerstin Eberhardt; Kjell Jonsson; Pierre Geborek
Early changes in bone mineral density measured by digital X-ray radiogrammetry predict up to 20 years radiological outcome in rheumatoid arthritis.
Arthritis research & therapy 2011;13(1):R31.
2011: Julia F Simard; Elizabeth V Arkema; Anders Sundström; Pierre Geborek; Tore Saxne; Eva Baecklund; Lars Coster; Christina Dackhammar; Lennart Jacobsson; Nils Feltelius; Staffan Lindblad; Solbritt Rantapää-Dahlqvist; Lars Klareskog; Ronald van Vollenhoven; Martin Neovius; Johan Askling
Ten years with biologics: to whom do data on effectiveness and safety apply?
Rheumatology (Oxford, England) 2011;50(1):204-13.
2011: Lars Erik Kristensen; A K Jakobsen; E M Bartels; Pierre Geborek; H Bliddal; Tore Saxne; B Danneskiold-Samsøe; R Christensen
The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials.
Scandinavian journal of rheumatology 2011;40(1):1-7.
2010: Tor Olofsson; Martin Englund; Tore Saxne; Anna Jöud; L T H Jacobsson; Pierre Geborek; Saralynn Allaire; Ingemar F Petersson
Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists: a population-based controlled cohort study.
Annals of the rheumatic diseases 2010;69(12):2131-6.
2010: Anders Gülfe; Lars Erik Kristensen; Tore Saxne; L T H Jacobsson; Ingemar F Petersson; Pierre Geborek
Utility-based outcomes made easy: the number needed per quality-adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden.
Arthritis care & research 2010;62(10):1399-406.
2010: Martin Englund; Anna Jöud; Pierre Geborek; David T Felson; L T H Jacobsson; Ingemar F Petersson
Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics.
Rheumatology (Oxford, England) 2010;49(8):1563-9.
2010: Anders Gülfe; Lars Erik Kristensen; Tore Saxne; L T H Jacobsson; Ingemar F Petersson; Pierre Geborek
Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden.
Annals of the rheumatic diseases 2010;69(2):352-7.
2010: M C Kapetanovic; Elisabet Lindqvist; M Simonsson; Pierre Geborek; Tore Saxne; Kerstin Eberhardt
Prevalence and predictive factors of comorbidity in rheumatoid arthritis patients monitored prospectively from disease onset up to 20 years: lack of association between inflammation and cardiovascular disease.
Scandinavian journal of rheumatology 2010;39(5):353-9.
2009: Johan Askling; Ronald van Vollenhoven; Fredrik Granath; Pauline Raaschou; C Michael Fored; Eva Baecklund; Christina Dackhammar; Nils Feltelius; Lars Cöster; Pierre Geborek; L T H Jacobsson; Staffan Lindblad; Solbritt Rantapää-Dahlqvist; Tore Saxne; Lars Klareskog
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Arthritis and rheumatism 2009;60(11):3180-9.
2009: Robin Christensen; Lars Erik Kristensen; Pierre Geborek; Bente Danneskiold-Samsøe; Tore Saxne; Henning Bliddal
[The efficacy of the three available anti-tumour necrosis factor therapies in patients with rheumatoid arthritis. A meta-analytic literature review--secondary publication].
Ugeskrift for laeger 2009;171(26):2192-4.
2009: Maria K Söderlin; Lennart T H Jacobsson; Ingemar F Petersson; Martin Englund; Tore Saxne; Pierre Geborek
Differences in longitudinal disease and treatment characteristics of patients with rheumatoid arthritis replying and not replying to a postal questionnaire. Experience from a biologics register in southern Sweden.
The Journal of rheumatology 2009;36(6):1166-9.
2009: Peter Lindgren; Pierre Geborek; Gisela Kobelt
Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.
International journal of technology assessment in health care 2009;25(2):181-9.
2009: Anders Gülfe; Lars Erik Kristensen; Pierre Geborek
Six and 12 weeks treatment response predicts continuation of tumor necrosis factor blockade in rheumatoid arthritis: an observational cohort study from southern Sweden.
The Journal of rheumatology 2009;36(3):517-21.
2009: L E Kristensen; Pierre Geborek; Tore Saxne
Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the South Swedish Arthritis Treatment Group register.
Rheumatology (Oxford, England) 2009;48(3):243-5.
2009: Gunnel Sandqvist; Pia Malcus Johnsson; Anna-Lena Sturesson; Magnus Tägil; Pierre Geborek
Measures and time points relevant for post-surgical follow-up in patients with inflammatory arthritis: a pilot study.
BMC musculoskeletal disorders 2009;10():50.
2009: Anders Gülfe; Daniel Aletaha; Tore Saxne; Pierre Geborek
Disease activity level, remission and response in established rheumatoid arthritis: performance of various criteria sets in an observational cohort, treated with anti-TNF agents.
BMC musculoskeletal disorders 2009;10():41.
2008: L E Kristensen; Meliha C Kapetanovic; Anders Gülfe; M Söderlin; Tore Saxne; Pierre Geborek
Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.
Rheumatology (Oxford, England) 2008;47(4):495-9.
2008: J A Karlsson; L E Kristensen; Meliha C Kapetanovic; Anders Gülfe; Tore Saxne; Pierre Geborek
Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register.
Rheumatology (Oxford, England) 2008;47(4):507-13.
2008: Kerstin Eberhardt; Gunnel Sandqvist; Pierre Geborek
Hand function tests are important and sensitive tools for assessment of treatment response in patients with rheumatoid arthritis.
Scandinavian journal of rheumatology 2008;37(2):109-12.
2008: Lars Erik Kristensen; Anders Gülfe; Tore Saxne; Pierre Geborek
Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register.
Annals of the rheumatic diseases 2008;67(3):364-9.
2007: Morten Svenson; Pierre Geborek; Tore Saxne; Klaus Bendtzen
Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies.
Rheumatology (Oxford, England) 2007;46(12):1828-34.
2007: Lars Erik Kristensen; R Christensen; H Bliddal; Pierre Geborek; B Danneskiold-Samsøe; Tore Saxne
The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review.
Scandinavian journal of rheumatology 2007;36(6):411-7.
2007: Johan Askling; C Michael Fored; Lena Brandt; Eva Baecklund; Lennart Bertilsson; Nils Feltelius; Lars Cöster; Pierre Geborek; L T H Jacobsson; Staffan Lindblad; Jörgen Lysholm; Solbritt Rantapää-Dahlqvist; Tore Saxne; Ronald van Vollenhoven; Lars Klareskog
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.
Annals of the rheumatic diseases 2007;66(10):1339-44.
2007: L T H Jacobsson; Carl Turesson; Jan-Ake Nilsson; Ingemar F Petersson; Elisabet Lindqvist; Tore Saxne; Pierre Geborek
Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis.
Annals of the rheumatic diseases 2007;66(5):670-5.
2007: Meliha C Kapetanovic; Tore Saxne; Jan-Ake Nilsson; Pierre Geborek
Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.
Rheumatology (Oxford, England) 2007;46(4):608-11.
2007: Klaus Bendtzen; Pierre Geborek; Morten Svenson; Lotta Larsson; Meliha C Kapetanovic; Tore Saxne
[Treatment of rheumatoid arthritis (RA) with anti-TNF-alpha antibody (Remicade). Individual monitoring of bioavailability and immunogenicity--secondary publication].
Ugeskrift for laeger 2007;169(5):420-3.
2007: Dirk M Wuttge; Marie Wildt; Pierre Geborek; Frank A Wollheim; Agneta Scheja; Anita Akesson
Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung disease.
Arthritis research & therapy 2007;9(5):R85.
2006: Klaus Bendtzen; Pierre Geborek; Morten Svenson; Lotta Larsson; Meliha C Kapetanovic; Tore Saxne
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
Arthritis and rheumatism 2006;54(12):3782-9.
2006: Johan Askling; C Michael Fored; Pierre Geborek; L T H Jacobsson; Ronald van Vollenhoven; Nils Feltelius; Staffan Lindblad; Lars Klareskog
Swedish registers to examine drug safety and clinical issues in RA.
Annals of the rheumatic diseases 2006;65(6):707-12.
2006: Carl Turesson; Lennart Jacobsson; Tore Saxne; Pierre Geborek
[Serious lung disease in RA and TNF-blockade--is there a connection?].
Läkartidningen 2006;103(5):308; author reply 308-9.
2006: Lars Erik Kristensen; Tore Saxne; Pierre Geborek
The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden.
Arthritis and rheumatism 2006;54(2):600-6.
2006: Lars Erik Kristensen; Tore Saxne; Jan-Ake Nilsson; Pierre Geborek
Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden.
Arthritis research & therapy 2006;8(6):R174.
2006: Meliha C Kapetanovic; Lotta Larsson; Lennart Truedsson; Gunnar Sturfelt; Tore Saxne; Pierre Geborek
Predictors of infusion reactions during infliximab treatment in patients with arthritis.
Arthritis research & therapy 2006;8(4):R131.
2006: Meliha C Kapetanovic; Tore Saxne; Anders G Sjöholm; Lennart Truedsson; Göran Jönsson; Pierre Geborek
Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.
Rheumatology (Oxford, England) 2006;45(1):106-11.
2005: Pierre Geborek; E Nitelius; S Noltorp; H Petri; L Jacobsson; L Larsson; Tore Saxne; I Leden
Population based studies of biological antirheumatic drug use in southern Sweden: comparison with pharmaceutical sales.
Annals of the rheumatic diseases 2005;64(12):1805-7.
2005: Johan Askling; C Michael Fored; Eva Baecklund; Lena Brandt; Carin Backlin; Anders Ekbom; C Sundström; Lennart Bertilsson; Lars Cöster; Pierre Geborek; L T H Jacobsson; Staffan Lindblad; Jörgen Lysholm; Solbritt Rantapää-Dahlqvist; Tore Saxne; Lars Klareskog; Nils Feltelius
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
Annals of the rheumatic diseases 2005;64(10):1414-20.
2005: Johan Askling; C Michael Fored; Lena Brandt; Eva Baecklund; Lennart Bertilsson; Nils Feltelius; Lars Cöster; Pierre Geborek; L T H Jacobsson; Staffan Lindblad; Jörgen Lysholm; Solbritt Rantapää-Dahlqvist; Tore Saxne; Lars Klareskog
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.
Annals of the rheumatic diseases 2005;64(10):1421-6.
2005: Anders Gülfe; Pierre Geborek; Tore Saxne
Response criteria for rheumatoid arthritis in clinical practice: how useful are they?
Annals of the rheumatic diseases 2005;64(8):1186-9.
2005: L T H Jacobsson; Carl Turesson; Anders Gülfe; Meliha C Kapetanovic; Ingemar F Petersson; Tore Saxne; Pierre Geborek
Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.
The Journal of rheumatology 2005;32(7):1213-8.
2005: Johan Askling; C Michael Fored; Lena Brandt; Eva Baecklund; Lennart Bertilsson; Lars Cöster; Pierre Geborek; L T H Jacobsson; Staffan Lindblad; Jörgen Lysholm; Solbritt Rantapää-Dahlqvist; Tore Saxne; Victoria Romanus; Lars Klareskog; Nils Feltelius
Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.
Arthritis and rheumatism 2005;52(7):1986-92.
2005: Pierre Geborek; Anna Bladström; Carl Turesson; A Gulfe; Ingemar F Petersson; Tore Saxne; Håkan Olsson; L T H Jacobsson
Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.
Annals of the rheumatic diseases 2005;64(5):699-703.
2005: Nils Feltelius; C Michael Fored; Paul Blomqvist; Lennart Bertilsson; Pierre Geborek; L T H Jacobsson; Staffan Lindblad; Jörgen Lysholm; Solbritt Rantapää-Dahlqvist; Tore Saxne; Lars Klareskog
Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept.
Annals of the rheumatic diseases 2005;64(2):246-52.
2004: Tore Saxne; Lotta Larsson; Pierre Geborek
Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al.
Arthritis and rheumatism 2004;50(9):3049-50; author reply 3050-1.
2004: Gisela Kobelt; Kerstin Eberhardt; Pierre Geborek
TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden.
Annals of the rheumatic diseases 2004;63(1):4-10.
2003: Meliha Crnkic; Bengt Månsson; Lotta Larsson; Pierre Geborek; Dick Heinegård; Tore Saxne
Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept.
Arthritis research & therapy 2003;5(4):R181-5.
2002: Elisabet Lindqvist; Tore Saxne; Pierre Geborek; Kerstin Eberhardt
Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage.
Annals of the rheumatic diseases 2002;61(12):1055-9.
2002: Pierre Geborek; M Crnkic; Ingemar F Petersson; Tore Saxne
Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.
Annals of the rheumatic diseases 2002;61(9):793-8.
2001: Agneta Scheja; Anita Akesson; Pierre Geborek; Marie Wildt; C B Wollheim; Frank A Wollheim; Ulrich Vischer
Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma).
Arthritis research 2001;3(3):178-82.
2001: B Mânsson; Anders Gülfe; Pierre Geborek; Dick Heinegård; Tore Saxne
Release of cartilage and bone macromolecules into synovial fluid: differences between psoriatic arthritis and rheumatoid arthritis.
Annals of the rheumatic diseases 2001;60(1):27-31.
2000: Pierre Geborek; Tore Saxne
Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis.
Rheumatology (Oxford, England) 2000;39(10):1159-61.
1997: Bengt Månsson; Pierre Geborek; Tore Saxne
Cartilage and bone macromolecules in knee joint synovial fluid in rheumatoid arthritis: relation to development of knee or hip joint destruction.
Annals of the rheumatic diseases 1997;56(2):91-6.